CELVIVO ApS - CVR: 35671099

2022, DKK

07.02.2024

Bruttoresultat

-1.489'

Primær drift

-21.450'

Årets resultat

-20.274'

Aktiver

41.732'

Kortfristede aktiver

15.166'

Egenkapital

-18.863'

Afkastningsgrad

-51 %

Soliditetsgrad

-45 %

Likviditetsgrad

26 %

Resultat

07.02.2024

Årsrapport	2022 07.02.2024	2021 01.02.2023	2020 08.02.2022	2019 30.11.2020	2018 12.06.2019	2017 29.05.2018	2016 17.05.2017
Nettoomsætning					311.063	201.735	203.712
Bruttoresultat	-1.489.033	-2.493.498	-1.039.875	-2.543.554	0	0	0
Resultat af primær drift	-21.449.914	-19.041.758	-5.943.694	-4.578.039	-35.368	-63.268	-7.663
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0
Finansielle indtægter	-69.805	20.400	7.690	0	0	0	0
Finansieringsomkostninger	-4.428.476	-2.606.277	-1.259.788	-213.546	0	0	0
Andre finansielle omkostninger	0	0	0	0	0	0	0
Resultat før skat	-26.047.190	-21.926.565	-7.195.792	-4.791.585	-35.368	-63.268	-7.663
Resultat	-20.274.329	-16.077.498	-4.726.905	-3.602.351	-36.424	-63.268	-7.663
Forslag til udbytte	0	0	0	0	0	0	0

Aktiver

07.02.2024

Årsrapport	2022 07.02.2024	2021 01.02.2023	2020 08.02.2022	2019 30.11.2020	2018 12.06.2019	2017 29.05.2018	2016 17.05.2017
Kortfristede varebeholdninger	2.461.312	2.611.134	855.925	28.710	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	12.680.146	8.531.297	6.538.594	3.591.827	0	0	0
Likvider	24.440	21.876	178.191	1.653.029	31.325	26.944	12.130
Kortfristede aktiver	15.165.898	11.164.307	7.572.710	5.273.566	31.325	26.944	12.130
Immaterielle aktiver og goodwill	23.804.600	23.823.335	20.285.049	10.044.408	0	0	0
Finansielle anlægsaktiver	138.970	138.970	141.276	49.546	0	0	0
Materielle aktiver	2.622.549	3.490.773	3.204.818	1.637.139	234.658	175.863	222.317
Langfristede aktiver	26.566.119	27.453.078	23.631.143	11.731.093	234.658	175.863	222.317
Aktiver	41.732.017	38.617.385	31.203.853	17.004.659	265.983	202.807	234.447

Aktiver

07.02.2024

Passiver

07.02.2024

Årsrapport	2022 07.02.2024	2021 01.02.2023	2020 08.02.2022	2019 30.11.2020	2018 12.06.2019	2017 29.05.2018	2016 17.05.2017
Forslag til udbytte	0	0	0	0	0	0	0
Egenkapital	-18.862.591	-21.543.108	-5.475.038	-1.132.734	230.625	139.539	201.417
Hensatte forpligtelser	0	0	1.312.171	1.253.415	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0
Anden langfristet gæld		322.232	322.232	385.580	0	0	0
Leverandører af varer og tjenesteydelser	2.386.525	1.119.189	1.233.764	2.128.846	0	0	0
Kortfristede forpligtelser	59.453.858	58.538.236	35.044.488	16.498.398	35.358	63.268	33.030
Gældsforpligtelser	60.594.608	60.160.493	35.366.720	16.883.978	35.358	63.268	33.030
Forpligtelser	60.594.608	60.160.493	35.366.720	16.883.978	35.358	63.268	33.030
Passiver	41.732.017	38.617.385	31.203.853	17.004.659	265.983	202.807	234.447

Passiver

07.02.2024

Nøgletal

07.02.2024

Årsrapport	2022 07.02.2024	2021 01.02.2023	2020 08.02.2022	2019 30.11.2020	2018 12.06.2019	2017 29.05.2018	2016 17.05.2017
Afkastningsgrad	-51,4 %	-49,3 %	-19,0 %	-26,9 %	-13,3 %	-31,2 %	-3,3 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	-11,7 %	-31,4 %	-3,8 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	107,5 %	74,6 %	86,3 %	318,0 %	-15,8 %	-45,3 %	-3,8 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-484,4 %	-730,6 %	-471,8 %	-2.143,8 %	Na.	Na.	Na.
Soliditestgrad	-45,2 %	-55,8 %	-17,5 %	-6,7 %	86,7 %	68,8 %	85,9 %
Likviditetsgrad	25,5 %	19,1 %	21,6 %	32,0 %	88,6 %	42,6 %	36,7 %

Resultat

07.02.2024

Gæld

07.02.2024

Årsrapport

07.02.2024

Nyeste:01.10.2022- 30.09.2023(offentliggjort: 07.02.2024)

Information om virksomhedens regnskabsklasse:The annual report for Celvivo ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

Beretning

07.02.2024

Dato for ledelsens godkendelse af årsrapporten:2024-01-15

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties about recognition or measurement Being a development stage enterprise, uncertainty exists associated with the assessment of the Company’s development activities and future earnings. As of September 30, 2023, the Company has recognized t. kr 16,953 concerning completed development projects. The value of the development projects depends on the company's ability to develop, market, and sell its main products ClinoStar and ClinoReactor at a profitable level. Management estimates that the implementation of the Company’s plans will be carried out in the foreseeable future. Management therefore considers the valuation reasonable. In case the company's sales and growth differ significantly from current plans, there may be uncertainty associated with the valuation. The Company has recognized tax assets with t. kr. 7. 102. Management expects that the Company's development activities will result in future positive earnings enabling the tax asset to be utilized within a period of 3-5 years.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Executive Board has approved the annual report of Celvivo ApS for the financial year 1 October 2022 - 30 September 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The principal activities of the company Like previous years, the principal activities of the Company are to operate in the biotechnology sector and related activities.